Hypobaric hypoxia of the pregnant rats was followed by the reduction of weight gain of the newborn pups, delayed impairment of memory (passive and active tasks) and changes of extrapolative water escape. Piracetam (200 mg/kg/day) administered at early postnatal period (from 8th to 20th day of life) corrected behavioral disturbances and physical development in rats. Postnatal therapy by nootropics didn't influence in adaptive behavior damaged by prenatal hypoxia.

Download full-text PDF

Source

Publication Analysis

Top Keywords

[behavior disorders
4
disorders rats
4
rats exposed
4
exposed intrauterine
4
intrauterine hypoxia
4
hypoxia correction
4
correction postnatal
4
postnatal treatment
4
treatment piracetam]
4
piracetam] hypobaric
4

Similar Publications

The burnout phenomenon is a subject of considerable interest due to its impact on both employee well-being and scientific inquiry. Workplace factors, both intrinsic and extrinsic, play a pivotal role in its development, often leading to job dissatisfaction and heightened burnout risk. Chronic stress and burnout induce significant dysregulation in the autonomic nervous system and hormonal pathways, alongside structural brain changes.

View Article and Find Full Text PDF

Safer chemical alternatives to bisphenol (BP) have been a major pursuit of modern green chemistry and toxicology. Using a chemical similarity-based approach, it is difficult to identify minor structural differences that contribute to the significant changes of toxicity. Here, we used omics and computational toxicology to identify chemical features associated with BP analogue-induced embryonic toxicity, offering valuable insights to inform the design of safer chemical alternatives.

View Article and Find Full Text PDF

Antipsychotic off-label use in the 21st century: An enduring public health concern.

Dialogues Clin Neurosci

December 2025

University Bordeaux, Inserm, Bordeaux Population Health Research Center, Team Pharmacoepidemiology, UMR 1219, Bordeaux, France.

Soon after the introduction of second-generation antipsychotics, antipsychotic off-label use (OLU) progressively became a common prescribing practice. This evolving practice should be regularly monitored considering the growing number of persons exposed to the adverse effects of antipsychotics. The aim of the present review was to synthesise the literature published over the last 15 years on antipsychotic OLU for mental health symptoms.

View Article and Find Full Text PDF

Seltorexant for major depressive disorder.

Expert Opin Emerg Drugs

January 2025

Department of Psychiatry, University of Toronto, Toronto, ON, Canada.

Introduction: Preclinical and clinical pharmacologic evidence indicate that orexin systems are relevant to sleep-wake cycle regulation and dimensions of reward and cognition, providing the basis to hypothesizing that they may be effective as therapeutics in mental disorders. Due to the limited efficacy and tolerability profiles of existing treatments for Major Depressive Disorder (MDD), investigational compounds in novel treatment classes are needed; seltorexant, an orexin receptor antagonist, is a potential new treatment currently under investigation.

Areas Covered: Mechanisms implicated in MDD, including reward and sleep are first overviewed.

View Article and Find Full Text PDF

Background: Telehealth services can increase access to care by reducing barriers. Telephone-administered care, in particular, requires few resources and may be preferred by communities in areas that are systemically underserved. Understanding the effectiveness of audio-based care is important to combat the current mental health crisis and inform discussions related to reimbursement privileges.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!